The human organic cation transporter OCT1 and its role as a target for drug responses

References

• Ahmadimoghaddam D, Zemankova L, Nachtigal P, Dolezelova E, Neumanova Z, Cerveny L, Ceckova M, Kacerovsky M, Micuda S, Staud F. 2013. Organic cation transporter 3 (OCT3/SLC22A3) and multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter in the placenta and fetal tissues: expression profile and fetus protective role at different stages of gestation. Biol Rep. 88(3):55.
   PubMed Web of Science ®Google Scholar
• Al-Abdulla R, Lozano E, Macias RIR, Monte MJ, Briz O, O'Rourke CJ, Serrano MA, Banales JM, Avila MA, Martinez-Chantar ML. 2018. Epigenetic events involved in OCT1-dependent impaired response of hepatocellular carcinoma to sorafenib. Br J Pharmacol. 176(6):787–800.
   Web of Science ®Google Scholar
• Al-Abdulla R, Lozano E, Macias RIR, Monte MJ, Briz O, O'Rourke CJ, Serrano MA, Banales JM, Avila MA, Martinez-Chantar ML, et al. 2019. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib. Br J Pharmacol. 176(6):787–800.
   PubMed Web of Science ®Google Scholar
• Andreev E, Brosseau N, Carmona E, Mes-Masson AM, Ramotar D. 2016. The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin. Sci Rep. 6(1):20508.
   PubMed Web of Science ®Google Scholar
• Arimany-Nardi C, Koepsell H, Pastor-Anglada M. 2015. Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions. Pharmacogenomics J. 15(6):473–487.
   PubMed Web of Science ®Google Scholar
• Arimany-Nardi C, Minuesa G, Keller T, Erkizia I, Koepsell H, Martinez-Picado J, Pastor-Anglada M. 2016. Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions. Front Pharmacol. 7:175.
   PubMed Web of Science ®Google Scholar
• Austin G, Holcroft A, Rinne N, Wang L, Clark RE. 2015. Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter hOCT1 in chronic myeloid leukaemia cells. Eur J Haematol. 94(1):74–78.
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. 2009. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 9(4):242–247.
   PubMed Web of Science ®Google Scholar
• Bexten M, Oswald S, Grube M, Jia J, Graf T, Zimmermann U, Rodewald K, Zolk O, Schwantes U, Siegmund W, et al. 2015. Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 12(1):171–178.
   PubMed Web of Science ®Google Scholar
• Boggon TJ, Eck MJ. 2004. Structure and regulation of Src family kinases. Oncogene. 23(48):7918–7927.
   PubMed Web of Science ®Google Scholar
• Bokelmann K, Brockmoller J, Tzvetkov MV. 2018. Impact of promoter polymorphisms on the transcriptional regulation of the organic cation transporter OCT1 (SLC22A1). J Pers Med. 8(4):42.
   PubMed Web of Science ®Google Scholar
• Breidert T, Spitzenberger F, Grundemann D, Schomig E. 1998. Catecholamine transport by the organic cation transporter type 1 (OCT1). Br J Pharmacol. 125(1):218–224.
   PubMed Web of Science ®Google Scholar
• Budiman T, Bamberg E, Koepsell H, Nagel G. 2000. Mechanism of electrogenic cation transport by the cloned organic cation transporter 2 from rat. J Biol Chem. 275(38):29413–29420.
   PubMed Web of Science ®Google Scholar
• Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C, Arndt P, Ulzheimer JC, Sonders MS, Baumann C, et al. 1998. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 54(2):342–352.
   PubMed Web of Science ®Google Scholar
• Busch AE, Quester S, Ulzheimer JC, Waldegger S, Gorboulev V, Arndt P, Lang F, Koepsell H. 1996. Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem. 271(51):32599–32604.
   PubMed Web of Science ®Google Scholar
• Cesar-Razquin A, Snijder B, Frappier-Brinton T, Isserlin R, Gyimesi G, Bai X, Reithmeier RA, Hepworth D, Hediger MA, Edwards AM, et al. 2015. A call for systematic research on solute carriers. Cell. 162(3):478–487.
   PubMed Web of Science ®Google Scholar
• Chen L, Shu Y, Liang X, Chen EC, Yee SW, Zur AA, Li S, Xu L, Keshari KR, Lin MJ, et al. 2014. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci USA. 111(27):9983–9988.
   PubMed Web of Science ®Google Scholar
• Chen L, Takizawa M, Chen E, Schlessinger A, Segenthelar J, Choi JH, Sali A, Kubo M, Nakamura S, Iwamoto Y, et al. 2010. Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther. 335(1):42–50.
   PubMed Web of Science ®Google Scholar
• Chen R, Nelson JA. 2000. Role of organic cation transporters in the renal secretion of nucleosides. Biochem Pharmacol. 60(2):215–219.
   PubMed Web of Science ®Google Scholar
• Choi MK, Song IS. 2012. Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharm Drug Dispos. 33(3):170–178.
   PubMed Web of Science ®Google Scholar
• Ciarimboli G, Schlatter E. 2005. Regulation of organic cation transport. Pflugers Arch. 449(5):423–441.
   PubMed Web of Science ®Google Scholar
• de Lima LT, Vivona D, Bueno CT, Hirata RD, Hirata MH, Luchessi AD, de Castro FA, de Lourdes FCM, Zanichelli MA, Chiattone CS, et al. 2014. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Med Oncol. 31(3):851.
   PubMed Web of Science ®Google Scholar
• DeGorter MK, Xia CQ, Yang JJ, Kim RB. 2012. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 52:249–273.
   PubMed Web of Science ®Google Scholar
• Denk GU, Soroka CJ, Mennone A, Koepsell H, Beuers U, Boyer JL. 2004. Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology. 39(5):1382–1389.
   PubMed Web of Science ®Google Scholar
• Deutsch B, Neumeister C, Schwantes U, Fromm MF, Konig J. 2019. Interplay of the organic cation transporters OCT1 and OCT2 with the apically localized export protein MATE1 for the polarized transport of trospium. Mol Pharm. 16(2):510–517.
   PubMed Web of Science ®Google Scholar
• Diao L, Shu Y, Polli JE. 2010. Uptake of pramipexole by human organic cation transporters. Mol Pharm. 7(4):1342–1347.
   PubMed Web of Science ®Google Scholar
• Du Plessis M, Pearce B, Jacobs C, Hoosain N, Benjeddou M. 2015. Genetic polymorphisms of the organic cation transporter 1 gene (SLC22A1) within the Cape Admixed population of South Africa. Mol Biol Rep. 42(3):665–672.
   PubMed Web of Science ®Google Scholar
• Duan P, Li S, You G. 2011. Transmembrane peptide as potent inhibitor of oligomerization and function of human organic anion transporter 1. Mol Pharmacol. 79(3):569–574.
   PubMed Web of Science ®Google Scholar
• Dujic T, Causevic A, Bego T, Malenica M, Velija-Asimi Z, Pearson ER, Semiz S. 2016. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes. Diabet Med. 33(4):511–514.
   PubMed Web of Science ®Google Scholar
• Egenberger B, Gorboulev V, Keller T, Gorbunov D, Gottlieb N, Geiger D, Mueller TD, Koepsell H. 2012. A substrate binding hinge domain is critical for transport-related structural changes of organic cation transporter 1. J Biol Chem. 287(37):31561–31573.
   PubMed Web of Science ®Google Scholar
• Engen JR, Wales TE, Hochrein JM, Meyn MA, Banu Ozkan S, Bahar I, Smithgall TE. 2008. Structure and dynamic regulation of Src-family kinases. Cell Mol Life Sci. 65(19):3058–3073.
   PubMed Web of Science ®Google Scholar
• Filippo CA, Ardon O, Longo N. 2011. Glycosylation of the OCTN2 carnitine transporter: study of natural mutations identified in patients with primary carnitine deficiency. Biochim Biophys Acta. 1812(3):312–320.
   PubMed Web of Science ®Google Scholar
• Forchap SL, Pirmohamed M, Clark RE. 2012. Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis. Leukemia. 26(3):490–498.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Galetin A, Huang SM. 2018. The international transporter consortium: summarizing advances in the role of transporters in drug development. Clin Pharmacol Ther. 104(5):766–771.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, et al. 2010. Membrane transporters in drug development. Nat Rev Drug Discov. 9(3):215–236.
   PubMed Web of Science ®Google Scholar
• Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE. 2008. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood. 112(8):3348–3354.
   PubMed Web of Science ®Google Scholar
• Giannoudis A, Wang L, Jorgensen AL, Xinarianos G, Davies A, Pushpakom S, Liloglou T, Zhang JE, Austin G, Holyoake TL, et al. 2013. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood. 121(4):628–637.
   PubMed Web of Science ®Google Scholar
• Gorboulev V, Volk C, Arndt P, Akhoundova A, Koepsell H. 1999. Selectivity of the polyspecific cation transporter rOCT1 is changed by mutation of aspartate 475 to glutamate. Mol Pharmacol. 56(6):1254–1261.
   PubMed Web of Science ®Google Scholar
• Gorbunov D, Gorboulev V, Shatskaya N, Mueller T, Bamberg E, Friedrich T, Koepsell H. 2008. High-affinity cation binding to organic cation transporter 1 induces movement of helix 11 and blocks transport after mutations in a modeled interaction domain between two helices. Mol Pharmacol. 73(1):50–61.
   PubMed Web of Science ®Google Scholar
• Grimm D, Lieb J, Weyer V, Vollmar J, Darstein F, Lautem A, Hoppe-Lotichius M, Koch S, Schad A, Schattenberg JM, et al. 2016. Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. BMC Cancer. 16:94.
   PubMed Web of Science ®Google Scholar
• Grinfeld J, Gerrard G, Alikian M, Alonso-Dominguez J, Ale S, Valganon M, Nteliopoulos G, White D, Marin D, Hedgley C, et al. 2013. A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. Br J Haematol. 163(5):631–639.
   PubMed Web of Science ®Google Scholar
• Gromicho M, Magalhaes M, Torres F, Dinis J, Fernandes AR, Rendeiro P, Tavares P, Laires A, Rueff J, Sebastiao Rodrigues A. 2013. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib. Oncology Reports. 29(2):741–750.
   PubMed Web of Science ®Google Scholar
• Grover B, Buckley D, Buckley AR, Cacini W. 2004. Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J Pharmacol Exp Ther. 308(3):949–956.
   PubMed Web of Science ®Google Scholar
• Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H. 1994. Drug excretion mediated by a new prototype of polyspecific transporter. Nature. 372(6506):549–552.
   PubMed Web of Science ®Google Scholar
• Gupta K, Donlan JAC, Hopper JTS, Uzdavinys P, Landreh M, Struwe WB, Drew D, Baldwin AJ, Stansfeld PJ, Robinson CV. 2017. The role of interfacial lipids in stabilizing membrane protein oligomers. Nature. 541(7637):421–424.
   PubMed Web of Science ®Google Scholar
• Gupta S, Wulf G, Henjakovic M, Koepsell H, Burckhardt G, Hagos Y. 2012. Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel. J Pharmacol Exp Ther. 341(1):16–23.
   PubMed Web of Science ®Google Scholar
• Hayer M, Bonisch H, Bruss M. 1999. Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1). Ann Hum Genet. 63(Pt 6):473–482.
   PubMed Web of Science ®Google Scholar
• Heemskerk S, Wouterse AC, Russel FG, Masereeuw R. 2008. Nitric oxide down-regulates the expression of organic cation transporters (OCT) 1 and 2 in rat kidney during endotoxemia. Europ J Pharmacol. 584(2–3):390–397.
   PubMed Web of Science ®Google Scholar
• Heise M, Lautem A, Knapstein J, Schattenberg JM, Hoppe-Lotichius M, Foltys D, Weiler N, Zimmermann A, Schad A, Grundemann D, et al. 2012. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer. 12(1):109.
   PubMed Web of Science ®Google Scholar
• Hendrickx R, Johansson JG, Lohmann C, Jenvert RM, Blomgren A, Borjesson L, Gustavsson L. 2013. Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 56(18):7232–7242.
   PubMed Web of Science ®Google Scholar
• Herraez E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM, Marin JJ, Briz O. 2013. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology. 58(3):1065–1073.
   PubMed Web of Science ®Google Scholar
• Hong M, Xu W, Yoshida T, Tanaka K, Wolff DJ, Zhou F, Inouye M, You G. 2005. Human organic anion transporter hOAT1 forms homooligomers. J Biol Chem. 280(37):32285–32290.
   PubMed Web of Science ®Google Scholar
• Horie A, Sakata J, Nishimura M, Ishida K, Taguchi M, Hashimoto Y. 2011. Mechanisms for membrane transport of metformin in human intestinal epithelial Caco-2 cells. Biopharm Drug Dispos. 32(5):253–260.
   PubMed Web of Science ®Google Scholar
• Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, Latham V, Sullivan M. 2012. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 40(Database issue):D261–270.
   PubMed Web of Science ®Google Scholar
• Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. 2015. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 43(Database issue):D512–520.
   PubMed Web of Science ®Google Scholar
• Hu DG, Marri S, McKinnon RA, Mackenzie PI, Meech R. 2018. Deregulation of the genes that are involved in drug absorption, distribution, metabolism, and excretion (ADME genes) in hepatocellular carcinoma. J Pharmacol Exp Ther. 368(3):363–381.
   PubMed Web of Science ®Google Scholar
• Hyrsova L, Smutny T, Trejtnar F, Pavek P. 2016. Expression of organic cation transporter 1 (OCT1): unique patterns of indirect regulation by nuclear receptors and hepatospecific gene regulation. Drug Metab Rev. 48(2):139–158.
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Saito A, Yokoyama K, Morikawa M, Igarashi T, Tamai I. 2005. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 33(4):495–499.
   PubMed Web of Science ®Google Scholar
• Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, Sugiyama Y. 2012. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther. 340(2):393–403.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Pearce B, Du Plessis M, Hoosain N, Benjeddou M. 2014. Genetic polymorphisms and haplotypes of the organic cation transporter 1 gene (SLC22A1) in the Xhosa population of South Africa. Genet Mol Biol. 37(2):350–359.
   PubMed Web of Science ®Google Scholar
• Jonker JW, Wagenaar E, Van Eijl S, Schinkel AH. 2003. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol. 23(21):7902–7908.
   PubMed Web of Science ®Google Scholar
• Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, Stellbrink HJ, Faetkenheuer G, Taubert D. 2008. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos. 36(8):1616–1623.
   PubMed Web of Science ®Google Scholar
• Kajiwara M, Terada T, Asaka J, Aoki M, Katsura T, Ikai I, Inui K. 2008. Regulation of basal core promoter activity of human organic cation transporter 1 (OCT1/SLC22A1). Am J Physiol Gastroint Liver Physiol. 295(6):G1211–1216.
   PubMed Web of Science ®Google Scholar
• Kang KW, Im YB, Go WJ, Han HK. 2009. C-myc amplification altered the gene expression of ABC- and SLC-transporters in human breast epithelial cells. Mol Pharm. 6(2):627–633.
   PubMed Web of Science ®Google Scholar
• Kanner BI. 2005. Molecular physiology: intimate contact enables transport. Nature. 437(7056):203–205.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. 2006. Dasatinib. Nat Rev Drug Discov. 5(9):717–718.
   PubMed Web of Science ®Google Scholar
• Karbach U, Kricke J, Meyer-Wentrup F, Gorboulev V, Volk C, Loffing-Cueni D, Kaissling B, Bachmann S, Koepsell H. 2000. Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol. 279(4):F679–687.
   PubMed Web of Science ®Google Scholar
• Kay BK, Williamson MP, Sudol M. 2000. The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. Faseb J. 14(2):231–241.
   PubMed Web of Science ®Google Scholar
• Keller T, Egenberger B, Gorboulev V, Bernhard F, Uzelac Z, Gorbunov D, Wirth C, Koppatz S, Dotsch V, Hunte C, et al. 2011. The large extracellular loop of organic cation transporter 1 influences substrate affinity and is pivotal for oligomerization. J Biol Chem. 286(43):37874–37886.
   PubMed Web of Science ®Google Scholar
• Keller T, Gorboulev V, Mueller TD, Dotsch V, Bernhard F, Koepsell H. 2019. Rat Organic Cation Transporter 1 Contains Three Binding Sites for Substrate 1-Methyl-4-phenylpyridinium per Monomer. Mol Pharmacol. 95(2):169–182.
   PubMed Web of Science ®Google Scholar
• Keller T, Schwarz D, Bernhard F, Dotsch V, Hunte C, Gorboulev V, Koepsell H. 2008. Cell free expression and functional reconstitution of eukaryotic drug transporters. Biochemistry. 47(15):4552–4564.
   PubMed Web of Science ®Google Scholar
• Khelashvili G, Stanley N, Sahai MA, Medina J, LeVine MV, Shi L, De Fabritiis G, Weinstein H. 2015. Spontaneous inward opening of the dopamine transporter is triggered by PIP2-regulated dynamics of the N-terminus. ACS Chem Neurosci. 6(11):1825–1837.
   PubMed Web of Science ®Google Scholar
• Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. 2005. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokin. 20(5):379–386.
   PubMedGoogle Scholar
• Koepsell H. 2011. Substrate recognition and translocation by polyspecific organic cation transporters. Biological Chemistry. 392(1-2):95–101.
   PubMed Web of Science ®Google Scholar
• Koepsell H. 2013a. Polyspecific organic cation transporters and their biomedical relevance in kidney. Curr Opin Nephrol Hypertens. 22(5):533–538.
   PubMed Web of Science ®Google Scholar
• Koepsell H. 2013b. The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med. 34(2–3):413–435.
   PubMed Web of Science ®Google Scholar
• Koepsell H. 2019. Multiple binding sites in organic cation transporters require sophisticated procedures to identify interactions of novel drugs. Biol Chem. 400(2):195–207.
   PubMed Web of Science ®Google Scholar
• Koepsell H, Lips K, Volk C. 2007. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 24(7):1227–1251.
   PubMed Web of Science ®Google Scholar
• Komazawa H, Yamaguchi H, Hidaka K, Ogura J, Kobayashi M, Iseki K. 2013. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure. J Pharm Sci. 102(3):1086–1094.
   PubMed Web of Science ®Google Scholar
• Konig J, Zolk O, Singer K, Hoffmann C, Fromm MF. 2011. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. British Journal of Pharmacology. 163(3):546–555.
   PubMed Web of Science ®Google Scholar
• Koren-Michowitz M, Buzaglo Z, Ribakovsky E, Schwarz M, Pessach I, Shimoni A, Beider K, Amariglio N, Le Coutre P, Nagler A. 2014. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients. Eur J Haematol. 92(4):283–288.
   PubMed Web of Science ®Google Scholar
• Laganowsky A, Reading E, Allison TM, Ulmschneider MB, Degiacomi MT, Baldwin AJ, Robinson CV. 2014. Membrane proteins bind lipids selectively to modulate their structure and function. Nature. 510(7503):172–175.
   PubMed Web of Science ®Google Scholar
• Landreh M, Marklund EG, Uzdavinys P, Degiacomi MT, Coincon M, Gault J, Gupta K, Liko I, Benesch JL, Drew D, et al. 2017. Integrating mass spectrometry with MD simulations reveals the role of lipids in Na+/H + antiporters . Nat Commun. 8:13993.
   PubMed Web of Science ®Google Scholar
• Lautem A, Heise M, Grasel A, Hoppe-Lotichius M, Weiler N, Foltys D, Knapstein J, Schattenberg JM, Schad A, Zimmermann A, et al. 2013. Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. Int J Oncol. 42(4):1297–1304.
   PubMed Web of Science ®Google Scholar
• Levitzki A. 2013. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol. 53:161–185.
   PubMed Web of Science ®Google Scholar
• Liang X, Yee SW, Chien HC, Chen EC, Luo Q, Zou L, Piao M, Mifune A, Chen L, Calvert ME, et al. 2018. Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content. PLoS Biol. 16(4):e2002907.
   PubMed Web of Science ®Google Scholar
• Liu HC, Goldenberg A, Chen Y, Lun C, Wu W, Bush KT, Balac N, Rodriguez P, Abagyan R, Nigam SK. 2016. Molecular properties of drugs interacting with SLC22 transporters OAT1, OAT3, OCT1, and OCT2: a machine-learning approach. J Pharmacol Exp Ther. 359:s215–229.
   Web of Science ®Google Scholar
• Liu Y, Zheng X, Yu Q, Wang H, Tan F, Zhu Q, Yuan L, Jiang H, Yu L, Zeng S. 2016. Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin. Sci Transl Med. 8(348):348ra397.
   Web of Science ®Google Scholar
• Lonsdale D. 2006. A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives. Evid Based Complement Alternat Med. 3(1):49–59.
   PubMed Web of Science ®Google Scholar
• Maeda T, Yotsumoto T, Oyabu M, Tamai I. 2008. Effect of glucocorticoid receptor ligand dexamethasone on the expression of organic cation transporter in rat liver. Drug Metab Pharm. 23(1):67–72.
   Web of Science ®Google Scholar
• Martens C, Shekhar M, Borysik AJ, Lau AM, Reading E, Tajkhorshid E, Booth PJ, Politis A. 2018. Direct protein-lipid interactions shape the conformational landscape of secondary transporters. Nat Commun. 9(1):4151.
   PubMed Web of Science ®Google Scholar
• Martens C, Stein RA, Masureel M, Roth A, Mishra S, Dawaliby R, Konijnenberg A, Sobott F, Govaerts C, McHaourab HS. 2016. Lipids modulate the conformational dynamics of a secondary multidrug transporter. Nat Struct Mol Biol. 23(8):744–751.
   PubMed Web of Science ®Google Scholar
• Matthaei J, Kuron D, Faltraco F, Knoch T, Dos Santos Pereira JN, Abu Abed M, Prukop T, Brockmoller J, Tzvetkov MV. 2016. OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 99(6):633–641.
   PubMed Web of Science ®Google Scholar
• Matthaei J, Seitz T, Jensen O, Tann A, Prukop T, Tadjerpisheh S, Brockmoller J, Tzvetkov MV. 2019. OCT1 deficiency affects hepatocellular concentrations and pharmacokinetics of cycloguanil, the active metabolite of the antimalarial drug proguanil. Clin Pharmacol Ther. 105(1):190–200.
   PubMed Web of Science ®Google Scholar
• Meyer-Wentrup F, Karbach U, Gorboulev V, Arndt P, Koepsell H. 1998. Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem Biophys Res Commun. 248(3):673–678.
   PubMed Web of Science ®Google Scholar
• Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. 2010. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 298(4):F997–f1005.
   PubMed Web of Science ®Google Scholar
• Mohelnikova-Duchonova B, Brynychova V, Hlavac V, Kocik M, Oliverius M, Hlavsa J, Honsova E, Mazanec J, Kala Z, Melichar B, et al. 2013. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Cancer Chemother Pharmacol. 72(3):669–682.
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Ortega FJ, Rodriguez-Hermosa JI, Sabater M, Pardo G, Ricart W, Fernandez-Real JM. 2011. OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes. 60(1):168–176.
   PubMed Web of Science ®Google Scholar
• Moss DM, Liptrott NJ, Siccardi M, Owen A. 2015. Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. Front Pharmacol. 6:78.
   PubMed Web of Science ®Google Scholar
• Muller F, Konig J, Hoier E, Mandery K, Fromm MF. 2013. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochem Pharmacol. 86(6):808–815.
   PubMed Web of Science ®Google Scholar
• Nagel G, Volk C, Friedrich T, Ulzheimer JC, Bamberg E, Koepsell H. 1997. A reevaluation of substrate specificity of the rat cation transporter rOCT1. J Biol Chem. 272(51):31953–31956.
   PubMed Web of Science ®Google Scholar
• Nie W, Sweetser S, Rinella M, Green RM. 2005. Transcriptional regulation of murine Slc22a1 (Oct1) by peroxisome proliferator agonist receptor-alpha and -gamma. Am J Physiol Gastrointest Liver Physiol. 288(2):G207–212.
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Damme K, Schwab M. 2011. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol. 201(1):105–167.
   PubMedGoogle Scholar
• Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, Zanger UM, Keppler D, Schwab M, Schaeffeler E. 2009. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 50(4):1227–1240.
   PubMed Web of Science ®Google Scholar
• Nies AT, Schaeffeler E, van der Kuip H, Cascorbi I, Bruhn O, Kneba M, Pott C, Hofmann U, Volk C, Hu S, et al. 2014. Cellular uptake of imatinib into leukemic cells is independent of human Organic Cation Transporter 1 (OCT1). Clin Cancer Res. 20(4):985–994.
   PubMed Web of Science ®Google Scholar
• Nigam SK. 2015. What do drug transporters really do? Nat Rev Drug Discov. 14(1):29–44.
   PubMed Web of Science ®Google Scholar
• Nji E, Chatzikyriakidou Y, Landreh M, Drew D. 2018. An engineered thermal-shift screen reveals specific lipid preferences of eukaryotic and prokaryotic membrane proteins. Nat Commun. 9(1):4253.
   PubMed Web of Science ®Google Scholar
• Pace CN, Scholtz JM. 1998. A helix propensity scale based on experimental studies of peptides and proteins. Biophys J. 75(1):422–427.
   PubMed Web of Science ®Google Scholar
• Papaluca A, Ramotar D. 2016. A novel approach using C. elegans DNA damage-induced apoptosis to characterize the dynamics of uptake transporters for therapeutic drug discoveries. Sci Rep. 6:36026.
   PubMed Web of Science ®Google Scholar
• Pedersen BP, Kumar H, Waight AB, Risenmay AJ, Roe-Zurz Z, Chau BH, Schlessinger A, Bonomi M, Harries W, Sali A, et al. 2013. Crystal structure of a eukaryotic phosphate transporter. Nature. 496(7446):533–536.
   PubMed Web of Science ®Google Scholar
• Pelis RM, Dangprapai Y, Cheng Y, Zhang X, Terpstra J, Wright SH. 2012. Functional significance of conserved cysteines in the human organic cation transporter 2. Am J Physiol Renal Physiol. 303(2):F313–320.
   PubMed Web of Science ®Google Scholar
• Pelis RM, Suhre WM, Wright SH. 2006. Functional influence of N-glycosylation in OCT2-mediated tetraethylammonium transport. Am J Physiol Renal Physiol. 290(5):F1118–1126.
   PubMed Web of Science ®Google Scholar
• Pliotas C, Dahl AC, Rasmussen T, Mahendran KR, Smith TK, Marius P, Gault J, Banda T, Rasmussen A, Miller S, et al. 2015. The role of lipids in mechanosensation. Nat Struct Mol Biol. 22(12):991–998.
   PubMed Web of Science ®Google Scholar
• Popp C, Gorboulev V, Muller TD, Gorbunov D, Shatskaya N, Koepsell H. 2005. Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Mol Pharmacol. 67(5):1600–1611.
   PubMed Web of Science ®Google Scholar
• Pyle E, Kalli AC, Amillis S, Hall Z, Lau AM, Hanyaloglu AC, Diallinas G, Byrne B, Politis A. 2018. Structural Lipids Enable the Formation of Functional Oligomers of the Eukaryotic Purine Symporter UapA. Cell Chem Biol. 25(7):840–848 e844.
   PubMed Web of Science ®Google Scholar
• Rizwan AN, Burckhardt G. 2007. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res. 24(3):450–470.
   PubMed Web of Science ®Google Scholar
• Rulcova A, Krausova L, Smutny T, Vrzal R, Dvorak Z, Jover R, Pavek P. 2013. Glucocorticoid receptor regulates organic cation transporter 1 (OCT1, SLC22A1) expression via HNF4alpha upregulation in primary human hepatocytes. Pharm Rep PR. 65(5):1322–1335.
   PubMed Web of Science ®Google Scholar
• Saborowski M, Kullak-Ublick GA, Eloranta JJ. 2006. The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha. J Pharmacol Exp Ther. 317(2):778–785.
   PubMed Web of Science ®Google Scholar
• Sakata T, Anzai N, Shin HJ, Noshiro R, Hirata T, Yokoyama H, Kanai Y, Endou H. 2004. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun. 313(3):789–793.
   PubMed Web of Science ®Google Scholar
• Sanders MR, Findlay HE, Booth PJ. 2018. Lipid bilayer composition modulates the unfolding free energy of a knotted α-helical membrane protein. Proc Natl Acad Sci USA. 115(8):E1799–E1808.
   PubMed Web of Science ®Google Scholar
• Sato T, Masuda S, Yonezawa A, Tanihara Y, Katsura T, Inui K. 2008. Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochem Pharmacol. 76(7):894–903.
   PubMed Web of Science ®Google Scholar
• Schaeffeler E, Hellerbrand C, Nies AT, Winter S, Kruck S, Hofmann U, van der Kuip H, Zanger UM, Koepsell H, Schwab M. 2011. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med. 3(12):82.
   PubMed Web of Science ®Google Scholar
• Seitz T, Stalmann R, Dalila N, Chen J, Pojar S, Dos Santos Pereira JN, Kratzner R, Brockmoller J, Tzvetkov MV. 2015. Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1. Genome Med. 7(1):56.
   PubMed Web of Science ®Google Scholar
• Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, Kawamoto M, Johns SJ, DeYoung J, Carlson E, et al. 2003. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA. 100(10):5902–5907.
   PubMed Web of Science ®Google Scholar
• Snieder B, Brast S, Grabner A, Buchholz S, Schroter R, Spoden GA, Florin L, Salomon J, Albrecht T, Barz V, et al. 2019. Identification of the tetraspanin CD9 as an interaction partner of organic cation transporters 1 and 2. SLAS Discov. 24(9):904–914.
   PubMed Web of Science ®Google Scholar
• Sogame Y, Kitamura A, Yabuki M, Komuro S. 2009. A comparison of uptake of metformin and phenformin mediated by hOCT1 in human hepatocytes. Biopharm Drug Dispos. 30(8):476–484.
   PubMed Web of Science ®Google Scholar
• Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, Janke LJ, Cavaletti G, Shields AF, Sparreboom A. 2013. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci USA. 110(27):11199–11204.
   PubMed Web of Science ®Google Scholar
• Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, et al. 2016. A phosphotyrosine switch regulates organic cation transporters. Nat Commun. 7:10880.
   PubMed Web of Science ®Google Scholar
• Stein PL, Vogel H, Soriano P. 1994. Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice. Genes Dev. 8(17):1999–2007.
   PubMed Web of Science ®Google Scholar
• Sundelin E, Gormsen LC, Jensen JB, Vendelbo MH, Jakobsen S, Munk OL, Christensen M, Brosen K, Frokiaer J, Jessen N. 2017. Genetic polymorphisms in organic cation transporter 1 attenuates hepatic metformin exposure in humans. Clin Pharmacol Ther. 102(5):841–848.
   PubMed Web of Science ®Google Scholar
• Takeuchi A, Motohashi H, Okuda M, Inui K. 2003. Decreased function of genetic variants, Pro283Leu and Arg287Gly, in human organic cation transporter hOCT1. Drug Metab Pharm. 18(6):409–412.
   Google Scholar
• Tanaka K, Xu W, Zhou F, You G. 2004. Role of glycosylation in the organic anion transporter OAT1. J Biol Chem. 279(15):14961–14966.
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC, Brockmoller J. 2013. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol. 86(5):666–678.
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Matthaei J, Pojar S, Faltraco F, Vogler S, Prukop T, Seitz T, Brockmoller J. 2018. Increased systemic exposure and stronger cardiovascular and metabolic adverse reactions to fenoterol in individuals with heritable OCT1 deficiency. Clin Pharmacol Ther. 103(5):868–878.
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmoller J. 2012. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J. 12(1):22–29.
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Saadatmand AR, Lotsch J, Tegeder I, Stingl JC, Brockmoller J. 2011. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther. 90(1):143–150.
   PubMed Web of Science ®Google Scholar
• Umamaheswaran G, Praveen RG, Damodaran SE, Das AK, Adithan C. 2015. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. Clin Exp Med. 15(4):511–517.
   PubMed Web of Science ®Google Scholar
• van Montfoort JE, Muller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ. 2001. Comparison of “type I” and “type II” organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 298(1):110–115.
   Google Scholar
• Volk C, Gorboulev V, Budiman T, Nagel G, Koepsell H. 2003. Different affinities of inhibitors to the outwardly and inwardly directed substrate binding site of organic cation transporter 2. Mol Pharmacol. 64(5):1037–1047.
   PubMed Web of Science ®Google Scholar
• Volk C, Gorboulev V, Kotzsch A, Muller TD, Koepsell H. 2009. Five amino acids in the innermost cavity of the substrate binding cleft of organic cation transporter 1 interact with extracellular and intracellular corticosterone. Mol Pharmacol. 76(2):275–289.
   PubMed Web of Science ®Google Scholar
• Vollmar J, Lautem A, Closs E, Schuppan D, Kim YO, Grimm D, Marquardt JU, Fuchs P, Straub BK, Schad A, et al. 2017. Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis. Oncotarget. 8(70):115667–115680.
   PubMedGoogle Scholar
• Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y. 2003. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol. 63(4):844–848.
   PubMed Web of Science ®Google Scholar
• Wang L, Giannoudis A, Austin G, Clark RE. 2012. Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. Exp Hematol. 40(10):811–819 e812.
   PubMed Web of Science ®Google Scholar
• Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. 2008. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther. 83(2):258–264.
   PubMed Web of Science ®Google Scholar
• Watkins DB, Hughes TP, White DL. 2015. OCT1 and imatinib transport in CML: is it clinically relevant? Leukemia. 29(10):1960–1969.
   PubMed Web of Science ®Google Scholar
• Winter GE, Radic B, Mayor-Ruiz C, Blomen VA, Trefzer C, Kandasamy RK, Huber KV, Gridling M, Chen D, Klampfl T, et al. 2014. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nat Chem Biol. 10(9):768–773.
   PubMed Web of Science ®Google Scholar
• Yee SW, Brackman DJ, Ennis EA, Sugiyama Y, Kamdem LK, Blanchard R, Galetin A, Zhang L, Giacomini KM. 2018. Influence of transporter polymorphisms on drug disposition and response: a perspective from the international transporter consortium. Clin Pharmacol Ther. 104(5):803–817.
   PubMed Web of Science ®Google Scholar
• Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. 2006. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 319(2):879–886.
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Taub ME, Chothe PP, Chu X, Giacomini KM, Kim RB, Ray AS, Stocker SL, Unadkat JD, Wittwer MB, et al. 2018. Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance. Clin Pharmacol Ther. 104(5):890–899.
   PubMed Web of Science ®Google Scholar
• Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. 1997. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 51(6):913–921.
   PubMed Web of Science ®Google Scholar
• Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, et al. 2006. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 66(17):8847–8857.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hagenbuch B. 2019. Protein-protein interactions of drug uptake transporters that are important for liver and kidney. Biochem Pharmacol. 168:384–391.
   PubMed Web of Science ®Google Scholar
• Zhou F, Xu W, Hong M, Pan Z, Sinko PJ, Ma J, You G. 2005. The role of N-linked glycosylation in protein folding, membrane targeting, and substrate binding of human organic anion transporter hOAT4. Mol Pharmacol. 67(3):868–876.
   PubMed Web of Science ®Google Scholar